Mavengity Expands into B2B Research
Owner Marko Pargo Ivanov is now writing the B2B Research desk directly, turning Forrester and Gartner category reports into plain-English breakdowns for buyers.
Read the ArticleMGIC's chief executive wants bank capital rules to credit private mortgage insurance as a risk mitigant, and the loss-severity data back him up. He is also the most direct beneficiary of the change, and the counterparty risk his op-ed spends the least time on is the part regulators still have to weigh.
When trade talks collapsed and tariffs hit, both countries chose their targets with striking precision, hitting beer, lumber, and appliances while carefully sparing energy, the flows neither side can actually afford to disrupt.
A new NBER working paper finds SNAP soda restrictions cut soda purchases 12 percent, but up to 39 percent of that spending simply moved to other sugary drinks the bans do not cover. The policy changed a product. It barely touched the nutrient it was built to reduce.
A physician's essay arguing medicine should bring back the handshake rests on old, consistent evidence that patients want deliberate human connection. The data show the handshake was only ever the most common vehicle for that, not the requirement itself.
The FDA placed a clinical hold on Regenxbio's Hunter syndrome gene therapy after small spinal masses turned up in five patients years after dosing. The finding is not proof of harm, it is a demonstration that a permanent treatment's risks surface on the same timescale as its benefits.
Nurse practitioner programs can admit as many students as they want, but the 500 supervised clinical hours those students need to graduate depend on a scarce, unfunded resource, working clinicians willing to supervise them, and a paid-matching market has grown to fill the gap the schools never funded.
The Phase III success of Moderna and Merck's melanoma vaccine proved mRNA cancer therapy works, but the market's instinct to hand the whole prize to Moderna misses where the value actually flows, most of it to Merck's franchise and to every other company on the same platform.
American Banker's ranking of the best-performing large banks puts spread lenders and fee-driven wealth managers on the same list under the same metric. Half the winners barely resemble a bank at all, and return on equity is built to reward exactly that.
Wells Fargo accepted that some private banking clients would leave as it cut service lines. Those departures didn't evaporate, they organized into Fidelis Capital, a nearly $3 billion firm built from the bankers and clients the bank priced as acceptable churn.
Non-English intent signal is still under twenty percent of total volume industrywide, which means most platforms are seeing a fraction of the buying activity happening outside English language markets.
One vendor is explicitly competing on restraint, arguing that a plausible AI generated article that is subtly wrong is worse for a knowledge base than no article at all.
Forrester's own buyer guidance undercuts the AI pitch: providers are getting measurably more efficient, and there is little evidence yet that any of that efficiency is reaching customer pricing.
Forrester's guidance to buyers is blunt: having a data centre in the EU answers one sovereignty question out of four, and most vendor pitches stop at the first.
Forrester frames 2026's binding constraint as a workforce that cannot be trained fast enough, which makes this a services category built around people more than platforms.
Generative AI should have commoditized this category, and instead Forrester's criteria count kept climbing, because the moat was always licensed source access, not summarization.
Two of the category's most prominent independent players are now owned by the card networks they were supposed to route around.
Forrester's provider count nearly doubled in three years, and every other technology category in this series points at the same root cause: the software works and the organisation does not change.
Every reference customer for one vendor said they would buy again, which in PLM can mean genuine excellence or a customer base that has nowhere else to go once the evidence chain is built.
Owner Marko Pargo Ivanov is now writing the B2B Research desk directly, turning Forrester and Gartner category reports into plain-English breakdowns for buyers.
Read the ArticleWith James now writing full time for our Healthcare & Medical desk, Mavengity has formally expanded into dedicated medical authorship.
Read the ArticleEvery article on Mavengity is written by a dedicated topic desk and checked against current market practice.
Home, auto, life, and health coverage, explained clearly and checked against the fine print.
Browse InsuranceRates, refinancing, and first-time buyer strategy, without the jargon lenders assume you already know.
Browse MortgageBudgeting, saving, and everyday money habits that compound. No get-rich-quick promises.
Browse Personal FinanceContracts, consumer rights, and disputes, explained so you know where you stand.
Browse LegalHealth coverage and medical billing, broken down so surprise bills are less likely to surprise you.
Browse HealthcareGartner and Forrester categories for B2B, translated into plain-English analysis for buyers, not analyst-subscription holders.
Browse ResearchWe start from public rate filings, regulator guidance, and lender disclosures, not marketing copy.
If a term needs a footnote, we explain it in the sentence instead of hiding it in the fine print.
We flag trade-offs and blind spots, not just the upside, so you get the full picture before you decide.
Mavengity is reader-supported and editorially independent from the products we cover.